RM-055 / Revolution Medicines - LARVOL DELTA

The company also remains on track to initiate a first-in-human clinical trial evaluating RM-055, a representative from a novel class, during the fourth quarter of 2026 (GlobeNewswire)

First-in-human • New trial • Solid Tumor

Innovative New Class of RAS(ON) Inhibitors (GlobeNewswire) - "A compound from this class of RAS(ON) inhibitors, RM-055, was shown to drive deep and durable tumor regressions in preclinical PDAC and NSCLC models that had developed resistance to a RAS multi-selective inhibitor. The company plans to share more information about this new class of compounds at an upcoming scientific meeting, and plans to initiate a Phase 1 trial with the first compound from this class of RAS(ON) inhibitors in the fourth quarter of this year."

New P1 trial • Preclinical • Non Small Cell Lung Cancer • Pancreatic Ductal Adenocarcinoma

Revolution Medicines Approaches Pivotal 2026 Clinical Milestones (AD HOC NEWS) - “The most anticipated near-term event is the outcome of the Phase III RASolute 302 trial. This study is evaluating Daraxonrasib in patients with previously treated PDAC. Management has scheduled the release of the crucial top-line results for the first six months of 2026….Furthermore, the initiation of the first human clinical trial for a third compound, RM-055, is planned by the end of 2026.”

First-in-human • New trial • P3 data: top line • Pancreatic Ductal Adenocarcinoma • Solid Tumor